Trastuzumab for metastatic breast cancer: Real world outcomes from an Australian whole-of-population cohort (2001-2016).

[1]  W. Cheung,et al.  Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2–Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes , 2019, Breast cancer : basic and clinical research.

[2]  B. Kiely,et al.  Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003–2015) , 2019, BMC Cancer.

[3]  A. Pandiella,et al.  Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors , 2019, Nanomaterials.

[4]  B. Kiely,et al.  Accentuating the Positive: Do Trials Give Unrealistic Expectations of Long-Term Survival? , 2019, JNCI cancer spectrum.

[5]  G. Minuti,et al.  Patterns of Care and Clinical Outcomes of HER2‐positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First‐line Trastuzumab‐based Therapy: A Multicenter Retrospective Cohort Study , 2017, Clinical breast cancer.

[6]  Gary H Lyman,et al.  Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Christine Y. Lu,et al.  Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort , 2017, BMJ Open.

[8]  P. Wise.  Cancer drugs, survival, and ethics , 2016, British Medical Journal.

[9]  R. Viney,et al.  Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer , 2016, PharmacoEconomics.

[10]  H. Bitterman,et al.  Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study , 2015, PloS one.

[11]  G. Minuti,et al.  Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. , 2015, The oncologist.

[12]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[13]  G. Fasola,et al.  Measures of outcome in metastatic breast cancer: insights from a real-world scenario. , 2014, The oncologist.

[14]  E. Wu,et al.  Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis , 2014, SpringerPlus.

[15]  H. Rugo,et al.  Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer , 2014, Breast Cancer Research and Treatment.

[16]  Yu Shen,et al.  First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer , 2014, Breast Cancer Research and Treatment.

[17]  C. Isaacs,et al.  Risk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population-based study , 2014, Breast Cancer Research and Treatment.

[18]  Christine Y. Lu,et al.  Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function? , 2013, Breast.

[19]  C. Y. Lu,et al.  Positive spillover effects of prescribing requirements: increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer , 2012, Internal medicine journal.

[20]  Sabine Tejpar,et al.  Molecular and clinical determinants of survival following relapse after treatment of stage ii-iii colon cancer (cc). results of the translational study on the petacc 3-eortc 40993-sakk 60-00 trial , 2010 .

[21]  M. Rawlins.  De testimonio: on the evidence for decisions about the use of therapeutic interventions , 2008, The Lancet.

[22]  J. Avorn.  In defense of pharmacoepidemiology--embracing the yin and yang of drug research. , 2007, The New England journal of medicine.

[23]  R. Ward,et al.  Trastuzumab and metastatic breast cancer: trastuzumab use in Australia--monitoring the effect of an expensive medicine access program. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[26]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[27]  A. Tutt,et al.  3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). , 2017, Breast.

[28]  C. la Vecchia,et al.  Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival. , 2016, European journal of cancer.

[29]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[30]  J. Thigpen,et al.  Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer , 2012 .